Sameem Abedin, MD¹, Guru Subramanian Guru Guru Murthy, MBBS², Mehdi Hamadani, MD³, Laura C. Michaelis, MD⁴, Lyndsey Runaas, MD^5*, Karen-Sue Carlson, MD, PhD⁶, Alexandra M. Harrington, MD, MT(ASCP)⁵ and Ehab L. Atallah, MD⁷

¹Division of Hematology/Oncology, Medical College of Wisconsin, Milwaukee, WI
²Division of Hematology/Oncology, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI
³Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
⁴Division of Hematology/Oncology, Department of Medicine, The Medical College of Wisconsin Inc., Milwaukee, WI
⁵Medical College of Wisconsin, Milwaukee, WI
⁶Versiti Blood Research Institute, Medical College of Wisconsin, Milwaukee, WI
⁷Medical College of Wisconsin, Wauwatosa, WI

Yngvar Floisand, MD, PhD^1*, Iris Bigalke, MD², Dag Josefsen, MD, PhD², Silke Raffegerst, PhD^3*, Frauke Schnorfeil, PhD^3*, Richard Addo, MD, PhD^3*, Dolores J. Schendel, PhD^3*, Kai Pinkernell, MD, MBA³ and Gunnar Kvalheim, MD, PhD^2*

¹Department of Hematology, Oslo University Hospital, Oslo, Norway
²Department of Cellular Therapy, Oslo University Hospital, Oslo, Norway
³Medigene Immunotherapies GmbH, Martinsried, Germany

Naveen Pemmaraju, MD¹, Giovanni Martinelli, MD², Elisabetta Todisco, MD PhD^3*, Andrew A Lane, MD, PhD⁴, Evelyn Acuña-Cruz, MD^5*, Eric Deconinck, MD PhD^6*, Eunice S. Wang, MD⁷, Kendra L. Sweet, MD, MS^8*, David A Rizzieri, MD⁹, Luca Mazzarella, MD PhD^10*, Daniel J. DeAngelo, MD, PhD¹¹, Pau Montesinos, MD, PhD^5*, Corrado Tarella^12*, Harry P. Erba, MD, PhD¹³, Marina Konopleva, MD, PhD¹⁴, Hagop M. Kantarjian, MD¹⁵, Callum M Sloss, PhD¹⁶, Kara E Malcolm, RN^16*, Patrick A Zweidler-McKay, MD, PhD¹⁷ and Naval Daver, MD¹⁸

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Institute of Hematology “L. e A. Seràgnoli”, Department of Experimental, Diagnostic and Specialty Medicine, Bologna, Italy
³European Institute of Oncology, Milano, Italy
⁴Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
⁵Hospital Universitari i Politècnic La Fe, Valencia, Spain
⁶Clinical Hematology, Besançon University Hospital, Besançon, France
⁷Roswell Park Comprehensive Cancer Center, BUFFALO, NY
⁸H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL
⁹Division of Hematologic Malignancies, Duke University, Durham, NC
¹⁰European Institute of Oncology, Milano, ITA
¹¹Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
¹²European Institute of Oncology, Milan, Italy
¹³Division of Hematologic Malignancies and Cellular Therapy, Duke University, Durham, NC
¹⁴Department of Leukemia, University of Texas, MD Anderson Cancer Center, Houston, TX
¹⁵University of Texas MD Anderson Cancer Center, Houston, TX
¹⁶ImmunoGen, Waltham, MA
¹⁷ImmunoGen, Lincoln, MA
¹⁸Department of Leukemia, The University of Texas, M.D. Anderson Cancer Center, Houston, TX

Arjan van de Loosdrecht, MD, PhD^1*, Janine van Elssen, MD PhD^2*, Bjørn Tore Gjertsen^3*, Eva Maria Wagner, MD⁴, Tobias Holderried, MD^5*, Uwe Platzbecker, MD⁶, Jacqueline J Cloos^7* and Jeroen Rovers, MD, PhD^8*

¹Department of Hematology, Amsterdam University Medical Center, VU University Medical Center, Cancer Center Amsterdam, Amsterdam, Netherlands
²Maastricht University Medical Center, Maastricht, Netherlands
³Department of Hematology, Institute of Clinical Science, University of Bergen, Bergen, Norway
⁴University Hospital Mainz, Universitären Centrums für Tumorerkrankungen, Mainz, Germany
⁵Department of Hematology, University of Bonn, Bonn, DEU
⁶Hematology and Cellular Therapy, University Hospital Leipzig, Leipzig, Germany
⁷Department of hematiology, Amsterdam UMC, location VUmc, Amsterdam, Amsterdam, Netherlands
⁸DCprime, Leiden, Netherlands

Shelley Herbrich, PhD¹, Natalia Baran, PhD, MD², Gheath Alatrash³, Eric Davis, MD^4*, Dongxing Zha, PhD^5* and Marina Konopleva, MD, PhD⁶

¹Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
²Department of Leukemia, The University of Texas M.D. Anderson Cancer Center, Houston, TX
³Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁴Department of Lymphoma and Myeloma, The University of Texas MD Anderson Cancer Center, Houston, TX
⁵Oncology Research for Biologics and Immunotherapy Translation (ORBIT), The University of Texas M.D. Anderson Cancer Center, Houston, TX
⁶University of Texas, MD Anderson Cancer Center, Houston, TX

Jacqueline S. Garcia, MD¹, Yael Flamand, MS^2*, Benjamin K. Tomlinson, MD³, Michael Keng, MD^4*, Lourdes M. Mendez, MD, PhD⁵, Samer Khaled, MD⁶, Asad Bashey, MD, PhD⁷, Andrew M. Brunner, MD⁸, Alexandra Savell, BS^1*, Donna Neuberg^9*, Ilene Galinsky^10*, Marlise R. Luskin, MD¹¹, David P. Steensma, MD¹, Martha Wadleigh, MD^10*, Eric S. Winer, MD¹⁰, David E. Avigan, MD¹², Nicole Cullen^11*, Scott Rodig, MD, PhD^13,14, Livius Penter^1*, R. Coleman Lindsley, MD, PhD¹, Stephanie Andrews^11*, Matthew S. Davids, MD¹, Catherine J. Wu, MD¹, Richard M. Stone, MD¹⁰, Daniel J. DeAngelo, MD, PhD¹⁵ and Robert J. Soiffer, MD¹⁶

¹Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
²Department of Data Science, Dana-Farber Cancer Institute, Boston, MA
³Case Western Reserve University, Cleveland, OH
⁴UVA, Charlottesville, VA
⁵Cancer Research Institute, Beth Israel Deaconess Cancer Center, Department of Medicine and Pathology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; Ludwig Center at Harvard, Harvard Medical School, Boston, MA, USA, Boston, MA
⁶Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA
⁷BMT Group of Georgia, Atlanta, GA
⁸Massachusetts General Hospital, Boston, MA
⁹DFCI, Los Angeles, CA
¹⁰Department of Medical Oncology, Dana-Farber Cancer Institute, Boston
¹¹Dana-Farber Cancer Institute, Boston, MA
¹²Beth Israel Deaconess Medical Center, Boston, MA
¹³Dana-Farber Cancer Institute, Center for Immuno-Oncology, Boston, MA
¹⁴Department of Pathology, Brigham & Women's Hospital, Boston, MA
¹⁵Department of Medical Oncology, Dana-Farber Cancer Inst., Boston, MA
¹⁶Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA